Triple test

WikiDoc Resources for Triple test
Articles
Most recent articles on Triple test Most cited articles on Triple test Review articles on Triple test Articles on Triple test in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Triple test Images of Triple test Photos of Triple test Podcasts & MP3s on Triple test Videos on Triple test
Evidence Based Medicine
Cochrane Collaboration on Triple test Bandolier on Triple test TRIP on Triple test
Clinical Trials
Ongoing Trials on Triple test at Clinical Trials.gov Trial results on Triple test Clinical Trials on Triple test at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Triple test NICE Guidance on Triple test NHS PRODIGY Guidance FDA on Triple test CDC on Triple test
Books
Books on Triple test
News
Triple test in the news Be alerted to news on Triple test News trends on Triple test
Commentary
Blogs on Triple test
Definitions
Definitions of Triple test
Patient Resources / Community
Patient resources on Triple test Discussion groups on Triple test Patient Handouts on Triple test Directions to Hospitals Treating Triple test Risk calculators and risk factors for Triple test
Healthcare Provider Resources
Symptoms of Triple test Causes & Risk Factors for Triple test Diagnostic studies for Triple test Treatment of Triple test
Continuing Medical Education (CME)
CME Programs on Triple test
International
Triple test en Espanol Triple test en Francais
Business
Triple test in the Marketplace Patents on Triple test
Experimental / Informatics
List of terms related to Triple test

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The triple test, also called triple screen, the Kettering test or the Bart's test, is an investigation performed during pregnancy (usually the second trimester).

Conditions detected

The most common abnormality the test can detect is fetal trisomy 21 (Down syndrome).

In addition to Down syndrome, the triple and quadruple tests preferentially identify fetal trisomy 18, Turner syndrome, triploidy, trisomy 16 mosaicism, fetal death, Smith-Lemli-Opitz syndrome, and steroid sulfatase deficiency.

Values measured

The triple test measures the following three levels in the maternal serum:

• alpha-fetoprotein (AFP)
• human chorionic gonadotropin (hCG)
• unconjugated estriol (UE₃)

Interpretation

Low values for AFP and UE₃ and high values for hCG and nuchal thickness suggest an increased risk of developing Down's Syndrome. High levels for AFP indicate possible neural tube defects like spina bifida. An estimated risk is calculated and adjusted for the expectant mother's age, weight and ethnicity; if she's diabetic; if she's having twins or other multiples and the gestational age of the fetus. Many of these factors affect the levels of the substances being measured and the interpretation of the results.

The test is for screening, not for diagnosis, and does not have nearly the same predictive power of amniocentesis or chorionic villus sampling. However, the screening test carries a much lower risk to the fetus, and in conjunction with the age-related risk by the patient is useful to indicate the need to proceed to the more invasive tests.

Variations

Only two of the hormones above can be tested for. Then the test is instead called a double test. In contrast, a quad test focuses on yet another hormone in addition. Furthermore, the triple test may be combined with an ultrasound measurement of nuchal translucency.

Double test

Only AFP and hCG are measured. However, the maternal age, weight, ethnicity etc. are still included. A double test is almost as effective as a triple test, because unconjugated estriol, the omitted hormone, is, in practice, not detected at a higher rate in people who have it, than in people without.

Quad test

The term "quadruple test" or "quad test" is sometimes used to refer to the above three tests plus a test for dimeric inhibin A (DIA).

References

Template:WH Template:WS